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Propositions
accompanying the thesis
Molecular alterations in endometrial cancer: 
implications for clinical management
1. Molecular subtyping can be successfully done on pre-operative endometrial cancer 
specimens. (this thesis)
2. POLE proofreading mutations predict favorable prognosis even in high-grade 
endometrial cancers. (this thesis) 
3. Molecular classification does not replace the traditional clinicopathological risk 
assessment but the combination refines the prediction of tumor behavior. (this thesis) 
4. Mismatch repair-deficiency testing is practical and feasible in endometrial cancer using 
a two-antibody immunohistochemical approach. (this thesis)
5. Tissue of origin determines mutation pattern in mismatch repair-deficient cancers. 
(Duval and Hamelin Cancer Res 2002, 62:2447-54; Ferreira et al. Hum mutat 2014, 
35:1514-23)
6. The dualistic Bokhman model of endometrial carcinoma is insufficient to encompass 
the diversity of endometrial cancers. (Murali et al. Lancet Oncol 2014, 15:268-78)
7. Even pathologists make mistakes, mostly in the field of gynecologic pathology. (Manion 
et al. Am J Surg Path 2008, 32:732-7)
8. Endometrial cancer is not your grandmother's cancer. (McAlpine et al. Cancer 2016, 
122:2787-98)
9. Chi dorme non piglia pesci. (Old Italian proverb)
10. Pipetteren kun je niet chagrijnig uitspreken (Paulien Cornelisse, in: Maar Ondertussen, 
2013) 
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